Analysts Set UiPath Inc. (NYSE:PATH) Target Price at $18.06

Shares of UiPath Inc. (NYSE:PATH) have been given a consensus rating of “Hold” by the eighteen analysts that are covering the stock, Marketbeat Ratings reports. Sixteen equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.06.

Several brokerages have commented on PATH. Royal Bank of Canada reissued a “sector perform” rating and set a $29.00 price target on shares of UiPath in a research report on Monday, April 1st. KeyCorp reaffirmed a “sector weight” rating on shares of UiPath in a report on Thursday, May 30th. TD Cowen reaffirmed a “hold” rating and issued a $17.00 target price (down from $28.00) on shares of UiPath in a report on Thursday, May 30th. Morgan Stanley dropped their target price on shares of UiPath from $25.00 to $15.00 and set an “equal weight” rating on the stock in a report on Thursday, May 30th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a report on Thursday, May 30th.

UiPath Trading Down 0.8 %

Shares of NYSE PATH opened at $11.93 on Friday. The firm has a market cap of $6.83 billion, a PE ratio of -74.56 and a beta of 0.86. UiPath has a 1-year low of $11.07 and a 1-year high of $27.87. The company has a fifty day moving average price of $16.56 and a 200 day moving average price of $21.01.

UiPath (NYSE:PATH) last issued its quarterly earnings results on Wednesday, May 29th. The healthcare company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The firm had revenue of $335.11 million for the quarter, compared to analysts’ expectations of $332.84 million. Equities research analysts forecast that UiPath will post -0.2 EPS for the current year.

Insider Buying and Selling

In other news, CFO Ashim Gupta sold 40,000 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $19.79, for a total transaction of $791,600.00. Following the completion of the transaction, the chief financial officer now owns 946,848 shares of the company’s stock, valued at $18,738,121.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.37% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UiPath

A number of hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in UiPath in the fourth quarter worth $165,749,000. Vanguard Group Inc. raised its position in UiPath by 7.6% in the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after acquiring an additional 2,673,718 shares during the period. Artisan Partners Limited Partnership bought a new stake in UiPath in the fourth quarter worth about $48,267,000. Glenmede Trust Co. NA raised its position in UiPath by 3,273.3% in the third quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock worth $26,777,000 after acquiring an additional 1,518,592 shares during the period. Finally, Vestmark Advisory Solutions Inc. bought a new stake in shares of UiPath in the fourth quarter valued at approximately $15,543,000. Institutional investors own 62.50% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.